Modality
Bispecific Ab
MOA
RAS(ON)i
Target
Tau
Pathway
Innate Imm
FL
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
Feb 2017
→ Jun 2031
Phase 2Current
NCT06184134
109 pts·FL
2021-09→2029-01·Recruiting
NCT07680096
1,952 pts·FL
2017-02→2031-06·Not yet recruiting
2,061 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-219mo awayPh1 Dose Esc· FL
2029-01-212.8y awayPh3 Readout· FL
2031-06-135.2y awayPh3 Readout· FL
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Not yet…
P2/3
Recruit…
Catalysts
Ph1 Dose Esc
2026-12-21 · 9mo away
FL
Ph3 Readout
2029-01-21 · 2.8y away
FL
Ph3 Readout
2031-06-13 · 5.2y away
FL
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06184134 | Phase 2/3 | FL | Recruiting | 109 | BodyWt |
| NCT07680096 | Phase 2/3 | FL | Not yet recr... | 1952 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 | |
| CGO-2579 | CG Oncology | Approved | TIGIT |